CP
PFE icon

Clayton Partners’s Pfizer PFE Stock Holding History

Clayton Partners’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-58,585
Closed -$1.69M – 40
2023
Q4 		$1.69M Sell
58,585
-8,108
-12% -$245K 1.37% 26
2023
Q3 		$2.21M Buy
66,693
+515
+0.8% +$18.2K 1.88% 21
2023
Q2 		$2.43M Sell
66,178
-421
-0.6% -$16.4K 2.1% 21
2023
Q1 		$2.72M Sell
66,599
-9,862
-13% -$426K 2.65% 16
2022
Q4 		$3.92M Buy
76,461
+10,232
+15% +$491K 3.71% 9
2022
Q3 		$2.9M Buy
66,229
+265
+0.4% +$12.9K 3.27% 11
2022
Q2 		$3.46M Sell
65,964
-229
-0.3% -$11.7K 3.73% 11
2022
Q1 		$3.43M Buy
66,193
+192
+0.3% +$9.96K 2.89% 13
2021
Q4 		$3.9M Buy
66,001
+4,973
+8% +$246K 3.4% 9
2021
Q3 		$2.63M Buy
61,028
+62
+0.1% +$2.75K 2.51% 19
2021
Q2 		$2.39M Buy
60,966
+2,566
+4% +$99.8K 2.01% 22
2021
Q1 		$2.12M Buy
+58,400
New +$2.07M 2.04% 21

Other funds holding PFE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Clayton Partners's PFE Position: Q1 2024 in Review

Clayton Partners sold out of Pfizer (PFE) in Q1 2024, closing a stake of 58,585 shares — an estimated $1.69M sold.

Clayton Partners first reported a position in PFE in Q1 2021 and held it in 12 quarters. The position peaked at $3.92M in Q4 2022. 2,874 funds tracked by Wall St. Rank hold PFE as of Q1 2024.

  • Clayton Partners reported no remaining Pfizer position as of Q1 2024 after selling out during the quarter.
  • Clayton Partners sold 58,585 Pfizer shares in Q1 2024, an estimated $1.69M.
  • Clayton Partners first reported a position in Pfizer in Q1 2021 and held it in 12 quarters.
  • Clayton Partners's Pfizer position peaked at $3.92M in Q4 2022.
  • 2,874 funds tracked by Wall St. Rank held Pfizer as of Q1 2024.

Based on Clayton Partners's 13F filing for Q1 2024, filed 14 May 2024.